{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:29:22Z","timestamp":1790310562429,"version":"4.1.0"},"reference-count":25,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3387,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1111\/j.1742-1241.2006.00987.x","type":"journal-article","created":{"date-parts":[[2006,5,24]],"date-time":"2006-05-24T11:31:12Z","timestamp":1148470272000},"page":"752-758","source":"Crossref","is-referenced-by-count":35,"title":["Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial"],"prefix":"10.1155","volume":"60","author":[{"given":"R.","family":"ROBERTS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"BAVENDAM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. B.","family":"GLASSER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"CARLSSON","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"EYLAND","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"ELINOFF","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2006,5,24]]},"reference":[{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","article-title":"The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society","volume":"61","author":"Abrams","year":"2003","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-3-12","article-title":"Patient-Reported Outcome and Quality of Life Instruments Database (PROQOLID): frequently asked questions","volume":"3","author":"Emery","year":"2005","journal-title":"Health Qual Life Outcomes"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1111\/j.1532-5415.2004.52423.x","article-title":"Clinical Global Impression of Change in Physical Frailty: development of a measure based on clinical judgment","volume":"52","author":"Studenski","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB4|cit4","first-page":"S580","article-title":"Overactive bladder significantly affects quality of life","volume":"6","author":"Abrams","year":"2000","journal-title":"Am J Manag Care"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1524-4733.2004.74008.x","article-title":"The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey","volume":"7","author":"Coyne","year":"2004","journal-title":"Value Health"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0090-4295(01)00986-4","article-title":"Health-related quality of life among adults with symptoms of overactive bladder: results from a U.S. community-based survey","volume":"57","author":"Liberman","year":"2001","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0149-2918(01)80104-1","article-title":"Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder","volume":"23","author":"Ricci","year":"2001","journal-title":"Clin Ther"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.1464-410X.2005.05722.x","article-title":"Assessment of bothersomeness and impact on quality of life of urinary incontinence in women in France, Germany, Spain and the UK","volume":"96","author":"Papanicolaou","year":"2005","journal-title":"BJU Int"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1742-1241.2006.00986.x","article-title":"Symptom-specific efficacy of tolterodine extended release in patients with overactive bladder: the IMPACT trial","volume":"60","author":"Elinoff","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/nau.20110","article-title":"Test-retest reliability of four questionnaires for patients with overactive bladder: the Overactive Bladder Questionnaire (OAB-q), Patient Perception of Bladder Condition (PPBC), Urgency Questionnaire (UQ), and the Primary OAB Symptom Questionnaire (POSQ)","volume":"24","author":"Matza","year":"2005","journal-title":"Neurourol Urodyn"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1023\/A:1016370925601","article-title":"Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q","volume":"11","author":"Coyne","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB13|cit13","first-page":"83","article-title":"Patient perception of bladder condition is a valid tool for evaluating the efficacy of overactive bladder therapy","volume":"13","author":"Coyne","year":"2002","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB14|cit14","volume-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0090-4295(03)00037-2","article-title":"American Urological Association Symptom Index for lower urinary tract symptoms in women: correlation with degree of bother and impact on quality of life","volume":"61","author":"Scarpero","year":"2003","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S1098-3015(10)61186-2","article-title":"Validation of the perception of bladder condition measure in overactive bladder","volume":"5","author":"Coyne","year":"2002","journal-title":"Value Health"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0149-2918(02)85137-2","article-title":"A multicenter, prospective, open-label study of tolterodine extended-release 4\u2003mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT)","volume":"24","author":"Siami","year":"2002","journal-title":"Clin Ther"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1472-8206.2004.00234.x","article-title":"Assessment of patient-reported outcomes in clinical trials: the example of health-related quality of life","volume":"18","author":"Wiklund","year":"2004","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB19|cit19","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2006.03.088","article-title":"Determining the importance of change in the OAB-q","author":"Coyne","year":"2006","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.urology.2004.02.029","article-title":"Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial","volume":"64","author":"Khullar","year":"2004","journal-title":"Urology"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/01.ju.0000181823.33224.a0","article-title":"Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"174","author":"Kaplan","year":"2005","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S0022-5347(01)67682-1","article-title":"Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism","volume":"153","author":"Yalla","year":"1995","journal-title":"J Urol"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1590\/S1677-55382004000200011","article-title":"International Prostate Symptom Score-IPSS-AUA as discriminate scale in 400 male patients with lower urinary tract symptoms (LUTS)","volume":"30","author":"Rodrigues","year":"2004","journal-title":"Int Braz J Urol"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB24|cit24","unstructured":"Michel MC Oelke M Goepel M et\u00a0al. What determines patient satisfaction in the treatment of overactive bladder"},{"key":"10.1111\/j.1742-1241.2006.00987.x-BIB25|cit25","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316771","volume-title":"Statistical Intervals: A Guide for Practitioners","author":"Hahn","year":"1991"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2006.00987.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2006.00987.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:04:24Z","timestamp":1643349864000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2006.00987.x"}},"subtitle":["IMPACT: TOLTERODINE ER IMPROVES PROS"],"short-title":[],"issued":{"date-parts":[[2006,5,24]]},"references-count":25,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2006.00987.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5,24]]}}}